TrialLung cancer (Amsterdam, Netherlands)2020

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.

David E Gerber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.